OvaScience

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
Munnybunny
Forum actieveling
Forum actieveling
Berichten: 923
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 380
Contact:

OvaScience

Berichtdoor Munnybunny » 18 Jan 2017 14:44

Hier zit misschien een mooie trade in..
Weerstand gebroken op $1,65, 26% short

4 huge events coming

Revising AUGMENT Strategy
OvaScience remains confident in the safety and efficacy of AUGMENT and will continue to offer the treatment to patients at partner clinics in Canada and Japan but will limit the growth of its commercial infrastructure in those countries. The Company is reassessing the ongoing IVI-sponsored clinical study in Spain as well as the planned multi-center clinical trial and will provide an update in the near-term.

Separately, OvaScience is scheduled to speak with the U.S. Food and Drug Administration in the first half of 2017, as part of its ongoing exploration of potential entry into the U.S. market.

Continuing Development of OvaPrime
OvaScience has decided to advance the clinical development of OvaPrime, a potential fertility treatment that could enable a woman to increase her egg reserve by repositioning her egg precursor (EggPCSM) cells within her ovary, where they may mature into fertilizable eggs. Diminished ovarian reserve affects approximately 30 percent of those seeking fertility treatment, and can preclude a woman from undergoing in vitro fertilization (IVF) if she produces, or has in the past produced, too few or no eggs following hormonal hyperstimulation. 1

The initial decision to begin first-in-human studies was based on positive safety data from a preclinical toxicology study in non-human primates. The repositioning of EggPC cells from the outer ovarian cortex to the inner ovarian cortex was demonstrated to be safe and well-tolerated in a six-month study of 18 non-human primates. The results of this toxicology study, along with supporting data from rodent models, were presented at Annual Meeting of the European Society of Human Reproduction and Embryology in 2016.2

To date, 40 patients are enrolled in the ongoing Company-sponsored clinical trial in Canada, which is designed to evaluate the safety of OvaPrime and changes in a patient’s hormone levels and follicular development as measured by ultrasound. OvaScience expects to enroll up to 50 patients in this study. Additionally, five patients have been enrolled in an ongoing investigator-initiated trial in the United Arab Emirates, which is designed to evaluate reproductive outcomes, as measured by egg quality, fertilization success and embryo quality. This trial continues to enroll patients.

In 2017, the Company will utilize the results of these studies to fully assess the safety profile of OvaPrime and to help define the patient population most likely to derive the greatest benefit from treatment. In the future, the Company will use these data to support OvaPrime’s commercial efforts. When these studies are complete, the data will be provided likely in the form of a presentation or publication.

Positive Development Progress of OvaTure in both Bovine and Human EggPC Cells
OvaScience has made significant progress toward advancing the preclinical development of OvaTure, its potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections by maturing EggPC cells into eggs in vitro, or outside of the body.

The Company is progressing towards maturation of an EggPC cell-derived egg. Together with Intrexon Corporation (NYSE: XON), an in vitro culture system has been established with the goal of developing oocytes that exhibit developmental competence, a critical milestone which indicates normal maturation. Signature hallmarks of developmental competence that have been observed in both bovine and human models include chromosomal segregation, germinal vesicles and polar bodies. Eggs generated by the OvaTure approach, which exhibit these hallmarks, should be fertilizable and develop into an embryo.

In bovine models, fertilization studies have begun to investigate the full development capabilities of EggPC cell-derived eggs and will be the focus for 2017. Also in 2017, OvaScience will continue efforts on human egg maturation as well as work with clinical partners to enable fertilization and characterization of EggPC cell-derived eggs and embryos.


Munnybunny
Forum actieveling
Forum actieveling
Berichten: 923
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 380
Contact:

Re: OvaScience

Berichtdoor Munnybunny » 18 Jan 2017 17:53

Ingestapt en nu wachten. APRI achterna zou mooi zijn :shock:

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 923
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 380
Contact:

Re: OvaScience

Berichtdoor Munnybunny » 25 Jan 2017 10:00

Volume en/of nieuws kan dit aandeel doen uitbreken.

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 923
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 380
Contact:

Re: OvaScience

Berichtdoor Munnybunny » 17 Feb 2017 15:10

OvaScience Inc. (OVAS) Moves Lower on Volume Spike for February 16

OvaScience Inc. is a Designs & develops fertility treatments technology


OvaScience Inc. (OVAS) traded on unusually high volume on Feb. 16, as the stock lost 7.5% to close at $1.48. On the day, OvaScience Inc. saw 1.95 million shares trade hands on 3,850 trades. Considering that the stock averages only a daily volume of 944,114 shares a day over the last month, this represents a pretty significant bump in volume over the norm.

Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances.

The stock has traded between $11.66 and $1.30 over the last 52-weeks, its 50-day SMA is now $1.95, and its 200-day SMA $5.00. OvaScience Inc. has a P/B ratio of 0.41.

OvaScience Inc is a life science company engaged in discovery, development, and commercialization of new fertility treatments for women. Its patented technology is based on scientific discoveries about the existence of egg precursor, or EggPC, cells.

Headquartered in Waltham, MA, OvaScience Inc. has 87 employees and is currently under the leadership of CEO Michelle Dipp.

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 923
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 380
Contact:

Re: OvaScience

Berichtdoor Munnybunny » 17 Feb 2017 15:13

Zacks estimated an EPS of $2.33 for OvaScience, Inc. (NASDAQ:OVAS)
By Lauren Corfield - February 17, 2017

https://topchronicle.com/zacks-estimate ... asdaqovas/

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 923
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 380
Contact:

Re: OvaScience

Berichtdoor Munnybunny » 03 Mar 2017 17:57

OvaScience Reports Fourth Quarter and Year-End 2016 Financial Results
OvaTure Program On Track to Successfully Fertilize a Bovine EggPC Cell-Derived Egg

50 Patients Enrolled in OvaPrime Clinical Trial

Cash Position Expected to Support Operations into Q12019


March 02, 2017 04:06 PM Eastern Standard Time
WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported financial results and provided a business update for the fourth quarter and year ended December 31, 2016.

“We are entering 2017 with continued confidence in our portfolio of potentially transformative fertility treatments and a strong belief in the potential of our EggPC platform to help women and couples build the families they deserve”
Tweet this
“We are entering 2017 with continued confidence in our portfolio of potentially transformative fertility treatments and a strong belief in the potential of our EggPC platform to help women and couples build the families they deserve,” said Michelle Dipp, M.D., Ph.D., Executive Chair and Co-Founder of OvaScience.

“In 2016, we achieved criteria indicative of developmental competence in EggPC cell-derived bovine and human eggs, an important step in the preclinical development of OvaTure, and we are on track to successfully fertilize a bovine EggPC cell-derived egg by year-end,” added Christophe Couturier, Chief Financial Officer. “We are also pleased to have enrolled the first 50 patients in our company-sponsored trial of OvaPrime, and to have started performing the first biopsies and reintroductions. With these milestones in hand, we remain on track to report initial data on our first 20 patients from this study by year-end. We are sufficiently funded to support the preclinical development of OvaTure and clinical development of OvaPrime into the first quarter of 2019.”

2016 and Recent Business Highlights:

OvaTureSM Treatment: The Company today reviewed progress for OvaTure, its potential next-generation in vitro fertilization (IVF) treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections by maturing egg precursor (EggPC SM) cells into eggs in vitro.

Progressing toward fertilization of EggPC cell-derived bovine egg and development of repeatable and robust process for maturation of EggPC cell-derived human eggs
There are a choreographed series of events that occur during egg maturation to prepare an egg for fertilization. Collectively, these can be described as developmental competence. Together with its partner, Intrexon Corporation (NYSE: XON), OvaScience has developed an in vitro cell culture process that has produced bovine and human eggs derived from EggPC cells that exhibit genetic, morphological and functional criteria of developmental competence during various phases of maturation. These criteria include: chromosomal segregation; an increase in cytoplasmic volume; the appearance of germinal vesicles, polar bodies and zona pellucida structures; and a positive brilliant cresyl blue (BCB) test.

Fertilization studies for bovine EggPC-cell derived eggs are underway and OvaScience and Intrexon expect to successfully fertilize a bovine EggPC-derived egg by year-end. OvaScience will continue to work with its clinical partners to develop a repeatable and robust process for the maturation of eggs derived from human EggPC cells and to secure authorization to fertilize human EggPC cell-derived eggs and embryos by the end of the first half of 2018.

OvaPrimeSM Treatment: The Company announced milestone achievements for OvaPrime, a potential fertility treatment that could enable a woman who makes too few or no eggs to increase her egg reserve.

Advancing clinical development
In December 2016, OvaScience announced its decision to continue the development of OvaPrime. OvaScience is currently evaluating OvaPrime in a prospective, blinded, randomized and controlled Company-sponsored trial, which is designed to assess the safety of OvaPrime and changes in a patient’s hormone levels and follicular development as measured by ultrasound. The trial will enroll 70 women with either diminished ovarian reserve (DOR) or primary ovarian insufficiency (POI). To date, the Company has enrolled 50 patients and expects to enroll an additional 20 women by the end of the first half of 2017.

OvaScience recently completed the first biopsies and reintroductions in this ongoing clinical trial in Canada. The Company remains on track to announce initial data from the first 20 patients, including six months of post-EggPC reintroduction safety data, by year-end.

AUGMENT SM Treatment: The Company maintained its commercial footprint for AUGMENT, a treatment designed to improve egg health and with that, IVF success rates, by using mitochondria from a woman’s own EggPC cells during IVF.

Revised commercial strategy
In December 2016, the Company announced that it will continue to make AUGMENT available to patients at clinics in Canada and Japan and will expand regionally on a limited basis as appropriate.

Reassessing clinical strategy
Also announced in December 2016, the Company is reassessing its clinical development strategy for AUGMENT, including its planned multi-center clinical trial and the ongoing IVI-sponsored study in Valencia, Spain.

Separately, OvaScience will meet with the U.S. Food and Drug Administration (FDA) in the first half of 2017, as part of its ongoing exploration of potential entry into the U.S. market.

Corporate Highlights:

In December 2016, OvaScience undertook a corporate restructuring to extend its cash position into the first quarter of 2019 and to increase its focus on the development of OvaTure and OvaPrime. In conjunction with this restructuring, the Company reduced its workforce by approximately 30 percent. Total restructuring costs of $6.8 million to $8.2 million are expected to result from this corporate restructuring, $5.4 million of which was recorded in 2016.
In 2016, seven new patents related to the Company’s treatments were issued, including one in the U.S. regarding antibody compositions and methods for isolating EggPC cells, a step common to all OvaScience treatments. In addition, in 2017, nearly 50 new applications covering more than 130 countries were filed, significantly extending the geographic reach of the Company’s patent portfolio. The Company now owns or otherwise controls 58 issued patents in 44 countries and more than 150 applications pending in more than 130 countries.
Upcoming 2017 Milestones:

The Company expects to achieve the following milestones in 2017:

OvaTure:
Fertilize a bovine EggPC cell-derived egg by year-end
OvaPrime:
Complete enrollment of all 70 patients in the ongoing Canadian study by the end of the first half of the year
Complete biopsies in all patients in the ongoing Canadian study by year-end
Provide initial read-out, including six months of post-EggPC reintroduction safety data from 20 patients, by year-end
AUGMENT:
Meet with the U.S. FDA to discuss potential market entry in the first half of the year
Fourth Quarter and Full Year 2016 Financial Results

Revenue for the quarter ended December 31, 2016 was $121,000, compared to $157,000 in the same period of 2015. Revenues for the full year 2016 were $653,000, compared to $277,000 in 2015. The Company recognized revenue related to 16 AUGMENT treatments in the fourth quarter of 2016, and related to 107 AUGMENT treatments in the full year 2016, including treatments offered under various pricing programs. In 2015, OvaScience recognized revenue from 22 AUGMENT treatments for the full fiscal year.

Net loss for the quarter ended December 31, 2016 was $22.6 million, or ($0.64) per share, as compared to net loss of $20.6 million, or ($0.76) per share, for the same period in 2015. Net loss for the full year ended December 31, 2016 was $82.3 million or ($2.56) per share, compared to net loss of $73.2 million or ($2.70) per share for the same period in 2015. The net loss for the quarter and year ended December 31, 2016 includes restructuring costs of $5.4 million.
Research and development expense for the quarter ended December 31, 2016, excluding restructuring costs, was $4.7 million, consistent with the same period in 2015. Research and development expense for the full year ended December 31, 2016, excluding restructuring costs, was $21.6 million, compared to $18.4 million in the same period in 2015. The year-over-year increase was primarily driven by a $3.9 million increase in employee compensation and related benefits driven by the hiring of additional research and development personnel, a $2.4 million increase in costs associated with certain ongoing research agreements, clinical studies and other costs, partially offset by a $3.3 million decrease in stock-based compensation expense related to certain mark-to-market adjustments of Founders’ stock, which was fully vested and expensed in the first quarter of 2015 that did not recur in 2016, and stock-based compensation expense for certain senior executives that did not recur in 2016 as a result of executive leadership changes.

Selling, general and administrative expense for the quarter ended December 31, 2016, excluding restructuring costs, was $10.9 million, compared to $14.6 million for the same period in 2015. This decrease was primarily driven by a $3.2 million decrease in stock-based compensation expense related to certain senior executives that did not recur in 2016 as a result of executive leadership changes in 2016, a $1.7 million decrease in costs related to international expansion preparation, including the establishment of certain international legal entities and international infrastructure, partially offset by a $1.2 million increase in costs related to commercialization efforts and overall business expansion, including increased marketing-related costs. Selling, general and administrative expense for the full year ended December 31, 2016 was $49.2 million, compared to $51.6 million in the same period in 2015. This decrease was primarily driven by a $7.2 million decrease in stock-based compensation expense related to certain senior executives that did not recur in 2016 as a result of executive leadership changes in 2016, as well as certain mark-to-market adjustments of Founders’ stock, which was fully vested and expensed in the first quarter of 2015 and did not recur in 2016, a $4.2 million decrease in costs related to international expansion preparation, including the establishment of certain international legal entities and international infrastructure, partially offset by a $4.7 million increase in costs related to commercialization efforts and overall business expansion, including increased marketing-related costs, and a $4.3 million increase in employee compensation and related benefits driven by the hiring of additional selling, general and administrative personnel.

At December 31, 2016, OvaScience had cash, cash equivalents and short-term investments of $114.4 million. OvaScience expects one-time cash expenditures of approximately $5.7 million to $6.5 million over 2017 and 2018 related to actions resulting from the corporate restructuring announced in December 2016. The Company may also incur further restructuring charges related to the restructuring plan. OvaScience’s operating cash burn for 2017 is expected to be between $45 million and $50 million, which excludes these one-time cash expenditures. OvaScience anticipates that it will have sufficient funds, without additional financing, to support its operating plan into the first quarter of 2019.

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 923
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 380
Contact:

Re: OvaScience

Berichtdoor Munnybunny » 13 Mar 2017 19:15

OvaScience is up 11.56% in midday trading to $1.64. Shares opened today at $1.47. The company has a 52-week low of $1.30 and a 52-week high of $11.66. On the Street’s front, the average 12-month analyst price target for the stock is $15.00, marking a 920.41% potential upside from current levels. In a report issued on March 3, H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on OVAS, with a price target of $15, which represents a potential upside of 920% from where the stock is currently trading. Separately, on the same day, Oppenheimer’s Derek Archila reiterated a Hold rating on the stock . Over the last 3 months, the insider sentiment on OvaScience has been positive based on 44 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 923
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 380
Contact:

Re: OvaScience

Berichtdoor Munnybunny » 11 Mei 2017 14:43

Terug aan het bekijken.


Today, I will highlight the recent progress across our portfolio of treatments beginning with OvaTure. OvaTure is our next-generation in vitro fertilization, or IVF treatment, that has the potential to help women produce healthy, young, fertilizable eggs without hormone injections.

This is by maturing EggPC cells into eggs in vitro. As the next-generation IVF treatment, OvaTure could be used in every woman seeking treatment for infertility, including those unable to undergo hormone hyperstimulation.

Over the last five years, our scientists together with our partner Intrexon have defined a culture process that supports the in vitro maturation of EggPC cells into eggs. The ultimate test to determine the maturation of a healthy egg and embryo is successful fertilization.

In 2017, we are focused on maturing bovine and human EggPC cells that are developmentally competent, meaning they exhibit certain characteristics that suggest the possibility of fertilization and development into embryo.

As we described last quarter, we have observed three key criteria of developmental competence, as applicable in both bovine and human EggPC cells-derived eggs. Through OvaXon, our joint venture with Intrexon, we can continue to progress fertilization studies for bovine EggPC cells-derived eggs.

We remain on track to achieve our goal of fertilizing a bovine egg by year-end. Beyond that, we expect to complete a bovine embryo transfer by the end of the first half of 2018 and ultimately to achieve the birth of a calf by the end of the first half of 2019. Importantly, our progress in the bovine model could serve as a proof-of-concept for our ongoing efforts in human.

....

And in the first quarter, we were pleased to welcome the first babies born to women treated in Japan. And just recently we were pleased to celebrate the second birthday of baby Zain, the first baby born using the AUGMENT treatment.

With regards to the United States, we recently met with the FDA regarding the AUGMENT treatment and we will continue to work with the agency under its available procedures to determine the most appropriate regulatory pathway for potential entry into the U.S. We will provide an update at the appropriate time in the future.

https://seekingalpha.com/article/407135 ... transcript

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 923
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 380
Contact:

Re: OvaScience

Berichtdoor Munnybunny » 22 Jun 2017 23:18

+30%

New chief at OvaScience; 50% of jobs cuts

OvaScience (NASDAQ:OVAS) appoints Christopher Kroeger, M.D., MBA, as CEO effective September 1 replacing Michelle Dipp, M.D., Ph.D., will transition to an advisory role. He joins the firm from Cardioxyl Pharmaceuticals where he was CEO.

Concurrently, the company will reduce its workforce by ~50% which will enable it to extend its cash runway into Q1 2020. Also, CFO Christophe Couturier will step down, succeeded by VP of Finance Jonathan Gillis.

2017 guidance update: cash consumption from operations will be lower than planned. Current resources should be sufficient to fund operations into Q1 2020.

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 923
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 380
Contact:

Re: OvaScience

Berichtdoor Munnybunny » 04 Aug 2017 10:39

OvaScience Reports Second Quarter 2017 Financial Results
– Fertilization of Bovine EggPC Cell-Derived Egg in OvaTure Program on Track for Year-End –

– Completed Target Enrollment in OvaPrime Clinical Safety Study; Expect to Announce Initial Safety Data in First 20 Patients by Year-End –

– Sufficiently Funded to Support Operations into 1Q 2020, Enabling Key Milestones –

– Conference Call Today at 4:30 p.m. ET –

August 03, 2017 04:02 PM Eastern Daylight Time
WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ:OVAS), a fertility company focused on the discovery, development and commercialization of new treatment options, today reported financial results and provided a business update for the second quarter ended June 30, 2017.

Second Quarter and Recent Business Highlights:

OvaTureSM Treatment: OvaTure is a potential next-generation in vitro fertilization (IVF) treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections by maturing egg precursor (EggPCSM) cells into eggs in vitro.

At the Midwest Reproductive Symposium International (MRSi) in June 2017, and the 50th Annual Meeting of the Society for the Study of Reproduction (SSR) in July 2017, OvaScience presented pre-clinical data which it believes demonstrate that bovine and human EggPC cell-derived eggs are similar to endogenous eggs with respect to key morphologic, genetic and functional criteria indicative of developmental competence. This suggests that bovine and human EggPC cells can be developed in vitro into eggs that exhibit key hallmarks of maturation.
OvaScience and Intrexon® (NYSE:XON) continue to progress fertilization studies for bovine EggPC-cell derived eggs. Starting in August 2017, Intrexon will perform pre-clinical bovine EggPC work for OvaScience under the OvaTure collaboration rather than under the OvaXonSM joint venture. Based on project plans provided by Intrexon, OvaScience continues to expect to fertilize a bovine EggPC cell-derived egg by the end of 2017 and is in discussions with Intrexon regarding the future of the OvaXon joint venture.

OvaScience continues to work with its clinical partners toward its goals of developing a repeatable and robust process for the maturation of human EggPC cells. The Company is also working toward securing authorization to fertilize human EggPC cell-derived eggs and characterizing the resulting embryos by the end of the first half of 2018.
OvaPrimeSM Treatment: OvaPrime is a potential fertility treatment that could enable a woman who makes too few or no eggs to increase her egg reserve, by transferring her EggPC cells to her own ovary, where they may mature into fertilizable eggs.

In June 2017, OvaScience announced that it has completed target enrollment of 70 patients in its ongoing prospective, controlled, blinded and randomized study of OvaPrime, which is designed to assess the treatment’s safety in women with either primary ovarian insufficiency (POI) or poor ovarian response (POR). Secondary endpoints include OvaPrime’s effect on patients’ anti-mullerian (AMH), follicle stimulating (FSH), and estradiol (E2) hormone levels, as well as follicular development, as measured by ultrasound. OvaScience expects to complete biopsies in 70 patients and to announce initial safety data from the first 20 patients by year-end.
AUGMENTSM Treatment: AUGMENT is a fertility treatment designed to improve egg health and with that, IVF success rates, by using mitochondria from a woman’s own EggPC cells during IVF.

In June 2017, OvaScience announced that it will continue to pursue business development opportunities for AUGMENT, while discontinuing its ongoing operations related to the AUGMENT treatment outside of North America. The Company is committed to minimizing the impact of this decision on women and families in affected areas.
Corporate Highlights:

In June 2017, OvaScience announced the appointment of Christopher Kroeger, M.D., M.B.A., as Chief Executive Officer, effective September 1, 2017. Dr. Kroeger brings substantial experience driving drug development and innovation in the life sciences and medical industries, and a strong clinical and research background as a physician and scientist. Upon Dr. Kroeger’s transition to OvaScience, Michelle Dipp, M.D., Ph.D., Co-Founder and Executive Chairman, will step down from the Board of Directors and serve in an advisory role. Richard Aldrich, Co-Founder of OvaScience and Partner of Longwood Fund, will continue to serve as lead independent director of the Board of Directors.
Also in June 2017, OvaScience undertook a corporate restructuring to align with its strategic focus on advancing OvaTure and OvaPrime and to extend its cash position into the first quarter of 2020. In conjunction with this restructuring, OvaScience reduced its workforce by approximately 50 percent.

Upcoming 2017 Milestones:

The Company expects to achieve the following milestones by year-end 2017:

OvaTure:
Fertilize a bovine EggPC cell-derived egg

OvaPrime:
Complete biopsies in 70 patients in the ongoing Canadian study
Provide initial data readout, including six months of post-EggPC reintroduction safety data from 20 patients

Second Quarter 2017 Financial Results:

Revenue for the quarter ended June 30, 2017 was $84,000, compared to $189,000 for the same period in 2016.
Research and development expense for the quarter ended June 30, 2017, excluding restructuring charges, was $5.0 million, compared to $6.0 million for the same period in 2016. This decrease was primarily driven by a $0.5 million decrease in employee related costs and stock-based compensation and a $0.5 million decrease in certain research agreements, both resulting from restructuring activities.

Selling, general and administrative expense for the quarter ended June 30, 2017, excluding restructuring charges, was $10.8 million, compared to $11.2 million for the same period in 2016. The decrease was driven by decreases of $1.4 million in employee related costs due to the Company’s reduced headcount, a $1.2 million decrease in marketing and commercial related costs, a $0.8 million decrease in travel, facilities and other costs primarily resulting from the Company’s restructuring activities. These decreases were offset by a $2.9 million increase in non-cash stock-based compensation, primarily driven by the modification of awards granted to an executive resulting in accelerated compensation expense. Of the $2.9 million increase, $2.3 million related to the June 2014 and December 2014 option grants. The Advisory Agreement has subsequently been amended to permit the accelerated vesting of those grants prior to December 31, 2018 only in the event of a future termination “without cause” or resignation for “good reason.”
Net loss for the quarter ended June 30, 2017 was $18.2 million, or ($0.51) per share, compared to a net loss of $18.6 million, or ($0.62) per share, for the same period in 2016. The net loss for the quarter ended June 30, 2017 includes restructuring charges of $2.0 million.

As of June 30, 2017, OvaScience had cash, cash equivalents and short-term investments of $86.6 million, compared to $114.4 million as of December 31, 2016. The cash outlays related to the restructurings in the first half of 2017 represent $4.1 million. OvaScience has incurred $8.9 million dollars of restructuring expenses to-date and expect total one-time cash expenditures resulting from the two restructurings to be between $8 and $9 million over 2017 and 2018. The Company may also incur further restructuring charges related to the restructuring plans. OvaScience anticipates that it will have sufficient funds, without additional financing, to support its operating plan into the first quarter of 2020.